ASCO 2022: Radiographic Progression in the Absence of PSA Progression in Patients with mHSPC: Post Hoc Analysis of ARCHES -

ASCO 2022 Post Hoc Analysis of ARCHES, phase III ARCHES trial, enzalutamide + ADT significantly reduced the risk of radiographic progression and increased overall survival in men with mHSPC, patients receiving enzalutamide + ADT versus ADT alone.